{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T08:56:17Z","timestamp":1789376177966,"version":"build-2803163510"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/jcp.0b013e3181845610","type":"journal-article","created":{"date-parts":[[2008,9,12]],"date-time":"2008-09-12T11:01:02Z","timestamp":1221217262000},"page":"509-517","source":"Crossref","is-referenced-by-count":30,"title":["The Association Between Carbamazepine and Valproate and Adverse Cutaneous Drug Reactions in Patients With Bipolar Disorder"],"prefix":"10.1097","volume":"28","author":[{"given":"Susan Shur-Fen","family":"Gau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Fong","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Jui","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Churn-Shiouh","family":"Gau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1001\/jama.1986.03380240052027","article-title":"Drug-induced cutaneous reactions. A report from the Boston collaborative drug surveillance program on 15,438 consecutive inpatients, 1975 to 1982.","volume":"24","author":"Bigby","year":"1986","journal-title":"JAMA"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs.","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1601-0825.2005.01141.x","article-title":"Mucosal disease series. Number IV. Erythema multiforme.","volume":"11","author":"Farthing","year":"2005","journal-title":"Oral Dis"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2165\/00002018-199513010-00007","article-title":"Drug-induced severe skin reactions. Incidence, management and prevention.","volume":"13","author":"Wolkenstein","year":"1995","journal-title":"Drug Saf"},{"key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archderm.1995.01690170041005","article-title":"Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes.","volume":"131","author":"Assier","year":"1995","journal-title":"Arch Dermatol"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study.","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch Dermatol"},{"key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.1990.01670250049006","article-title":"The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients.","volume":"126","author":"Chan","year":"1990","journal-title":"Arch Dermatol"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/archderm.1991.01680050083008","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany.","volume":"127","author":"Schopf","year":"1991","journal-title":"Arch Dermatol"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985.","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch Dermatol"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1111\/1523-1747.ep12388434","article-title":"The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification.","volume":"102","author":"Roujeau","year":"1994","journal-title":"J Invest Dermatol"},{"key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0190-9622(99)70508-6","article-title":"Stevens-Johnson syndrome limited to multiple sites of radiation therapy in a patient receiving phenobarbital.","volume":"40","author":"Duncan","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"R13-6-20210128","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF02113442","article-title":"Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection.","volume":"14","author":"Fournier","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2332\/allergolint.O-07-483","article-title":"Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006.","volume":"56","author":"Yamane","year":"2007","journal-title":"Allergol Int"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/0190-9622(90)70307-4","article-title":"Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases.","volume":"23","author":"Villada","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1445-5994.2005.00790.x","article-title":"Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study.","volume":"35","author":"Lin","year":"2005","journal-title":"Intern Med J"},{"key":"R17-6-20210128","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study group of the international case control study on severe cutaneous adverse reactions.","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00128071-200304010-00003","article-title":"Adverse cutaneous reactions to mood stabilizers.","volume":"4","author":"Warnock","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0305-4179(95)00140-9","article-title":"Toxic epidermal necrolysis in a burns centre: a 6-year review.","volume":"22","author":"Khoo","year":"1996","journal-title":"Burns"},{"key":"R20-6-20210128","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1046\/j.1365-4362.1998.00490.x","article-title":"Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia.","volume":"37","author":"Kamaliah","year":"1998","journal-title":"Int J Dermatol"},{"key":"R21-6-20210128","first-page":"119","article-title":"Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis antecedent drug exposures in 99 hospitalized patients.","volume":"14","author":"Li","year":"1996","journal-title":"Dematol Sinica"},{"key":"R22-6-20210128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4103\/0378-6323.16782","article-title":"Carbamazepine-the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years.","volume":"71","author":"Devi","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archderm.1994.01690050066011","article-title":"Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine.","volume":"130","author":"Friedmann","year":"1994","journal-title":"Arch Dermatol"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/WNL.53.6.1170","article-title":"Carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten.","volume":"53","author":"Arroyo","year":"1999","journal-title":"Neurology"},{"key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1176\/ajp.2006.163.8.1362","article-title":"Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile psychiatric prevalence study.","volume":"163","author":"Vicente","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R27-6-20210128","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.4088\/JCP.v66n1001","article-title":"Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the national epidemiologic survey on alcohol and related conditions.","volume":"66","author":"Grant","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R28-6-20210128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ps.55.6.691","article-title":"Prevalence of psychiatric disorders among national health insurance enrollees in Taiwan.","volume":"55","author":"Chien","year":"2004","journal-title":"Psychiatr Serv"},{"key":"R29-6-20210128","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0165-0327(00)00310-4","article-title":"Bipolar disorder in the general population in The Netherlands (prevalence, consequences and care utilisation): results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS).","volume":"68","author":"ten Have","year":"2002","journal-title":"J Affect Disord"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1176\/appi.ajp.159.6.1005","article-title":"Trends in the treatment of bipolar disorder by outpatient psychiatrists.","volume":"159","author":"Blanco","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R31-6-20210128","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1176\/ps.2007.58.1.85","article-title":"Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders.","volume":"58","author":"Baldessarini","year":"2007","journal-title":"Psychiatr Serv"},{"key":"R32-6-20210128","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1176\/ps.2007.58.4.554","article-title":"Trends in the use of psychotropic drugs in Taiwan: a population-based national health insurance study, 1997-2004.","volume":"58","author":"Chien","year":"2007","journal-title":"Psychiatr Serv"},{"key":"R33-6-20210128","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1034\/j.1399-5618.2000.020205.x","article-title":"Psychotropic drug prescription patterns among patients with bipolar I disorder.","volume":"2","author":"Levine","year":"2000","journal-title":"Bipolar Disord"},{"key":"R35-6-20210128","first-page":"416","article-title":"Erythema multiforme major in a patient treated with carbamazepine.","volume":"48","author":"Fawcett","year":"1987","journal-title":"J Clin Psychiatry"},{"key":"R36-6-20210128","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1600-0404.1990.tb00949.x","article-title":"Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system.","volume":"81","author":"Askmark","year":"1990","journal-title":"Acta Neurol Scand"},{"key":"R37-6-20210128","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/BF01954091","article-title":"Carbamazepine-induced skin rash in children with epilepsy.","volume":"152","author":"Konishi","year":"1993","journal-title":"Eur J Pediatr"},{"key":"R38-6-20210128","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2230.2006.02185.x","article-title":"Epidemiological study of severe cutaneous adverse drug reactions in a city district of China.","volume":"31","author":"Li","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"R39-6-20210128","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-4362.1993.tb02814.x","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand.","volume":"32","author":"Leenutaphong","year":"1993","journal-title":"Int J Dermatol"},{"key":"R40-6-20210128","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome.","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"R41-6-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study.","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R42-6-20210128","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/00004714-199810000-00012","article-title":"Valproic acid-induced Stevens-Johnson syndrome.","volume":"18","author":"Tsai","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"R43-6-20210128","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1212\/WNL.49.2.542","article-title":"Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study.","volume":"49","author":"Tennis","year":"1997","journal-title":"Neurology"},{"key":"R44-6-20210128","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2146\/ajhp060071","article-title":"Lamotrigine-induced Stevens-Johnson syndrome.","volume":"64","author":"Hilas","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"R45-6-20210128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-244X-7-33","article-title":"The management of bipolar mania: a national survey of baseline data from the EMBLEM study in Italy.","volume":"7","author":"Bellantuono","year":"2007","journal-title":"BMC Psychiatry"},{"key":"R46-6-20210128","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1176\/ps.2006.57.5.660","article-title":"Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants.","volume":"57","author":"Ghaemi","year":"2006","journal-title":"Psychiatr Serv"},{"key":"R47-6-20210128","first-page":"566","article-title":"Lamotrigine-related skin rashes in adults.","volume":"18","author":"Huang","year":"2002","journal-title":"Kaohsiung J Med Sci"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e3181845610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:57:36Z","timestamp":1620957456000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200810000-00006"}},"subtitle":["A Nested Matched Case-Control Study"],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181845610","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}